Histamine in immunotherapy of advanced melanoma: a pilot study

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  1994-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01534430PMID 8001030PMCID PMC11038298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biology of Natural Killer Cells

  2008cited by this paper
• A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma.

  1993cited by this paper
• Regulation of the Natural Killer Cell Response to Interferon-α by Biogenic Amines

  1992cited by this paper
• Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial.

  1992influential reference
• Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study.

  1991cited by this paper
• Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma.

  1991cited by this paper
• Cell‐to‐Cell Mediated Inhibition of Natural Killer Cell Proliferation by Monocytes and its Regulation by Histamine H2‐Receptors

  1991cited by this paper
• Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

  1990cited by this paper
• Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.

  1990cited by this paper
• Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2.

  1990cited by this paper
• Role of histamine in natural killer cell-mediated resistance against tumor cells.

  1990cited by this paper
• A Cell‐to‐Cell Mediated Interaction Involving Monocytes and Non‐T/CD16+ Natural Killer (NK) Cells is Required for Histamine H2‐Receptor‐Mediated NK‐Cell Activation

  1990cited by this paper
• Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

  1990cited by this paper
• Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection

  1989cited by this paper
• In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

  1987cited by this paper
• Histamine H2-receptor-mediated regulation of human natural killer cell activity.

  1986cited by this paper

• H2 antihistamines: May be useful for combination therapies in cancer?

  2024cites this paper
• CD44 Glycosylation as a Therapeutic Target in Oncology

  2022cites this paper
• Histamine in cancer immunology and immunotherapy. Current status and new perspectives

  2021cites this paper
• Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma

  2020cites this paper
• Pharmacological interventions part IV: Metabolic modifiers

  2020cites this paper
• Novel ruthenium(II) complexes with cimetidine: DFT calculations and in vitro cytotoxic activities against glioblastoma cell lines

  2020cites this paper
• Cytokines (IL-2, IFN GM-CSF etc) Melanoma

  2018cites this paper
• Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells.

  2013cites this paper
• EPR analysis of gamma irradiated single crystal cimetidine

  2013cites this paper
• Improving Outcomes in Advanced Malignant Melanoma

  2012cites this paper
• Reactive Oxygen Species in the Biology of Melanoma

  2011cites this paper
• Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.

  2008cites this paper
• Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.

  2007cites this paper
• Cimetidine inhibits epidermal growth factor‐induced cell signaling

  2007cites this paper
• Immunologic approaches to acute leukemia in the elderly.

  2006cites this paper
• Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review).

  2006cites this paper
• Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial.

  2005cites this paper
• Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).

  2005cites this paper
• Cimetidine inhibits angiogenesis and suppresses tumor growth.

  2005cites this paper
• Improving outcomes in advanced malignant melanoma: update on systemic therapy.

  2005cites this paper
• Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial.

  2004cites this paper
• Skin reactivity to histamine and expression of histamine receptors mRNA in lymphocytes of healthy subjects and non-small-cell lung cancer patients before and after surgery.

  2004cites this paper
• Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis

  2004cites this paper
• Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.

  2004cites this paper
• Cimetidine reduces impairment of cellular immunity after transcatheter arterial embolization in patients with hepatocellular carcinoma.

  2003cites this paper
• Systemic Treatment in Advanced Melanoma: Innovative Perspectives

  2003cites this paper
• Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN-alpha and histamine treatment during remission of non-Hodgkin's lymphoma.

  2003cites this paper
• The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma

  2003cites this paper
• Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice.

  2003cites this paper
• Histamine dihydrochloride and cancer.

  2003cites this paper
• Metastatic malignant melanoma.

  2003cites this paper
• Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.

  2002cites this paper
• Monotherapy with histamine dihydrochloride suppresses in vivo growth of a rat sarcoma in liver and subcutis.

  2002cites this paper
• IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells.

  2002cites this paper
• The use of histamine in cancer immunotherapy.

  2002cites this paper
• Histamine as an adjunct to immunotherapy.

  2002cites this paper
• Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat.

  2002cites this paper
• Therapeutic options in the management of renal cell carcinoma.

  2002cites this paper
• Histamine in cancer immunotherapy: a preclinical background.

  2002cites this paper
• Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia.

  2002cites this paper
• Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells

  2002cites this paper
• Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment

  2001cites this paper
• [Regulation of cytokine production by histamine through H2-receptor stimulation].

  2001cites this paper
• Both interferon (IFN)alpha and IFNgamma inhibit histidine decarboxylase expression in the HT168 human melanoma cell line.

  2000cites this paper
• Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma

  2000cites this paper
• Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression.

  2000cites this paper
• Alleviating oxidative stress in cancer immunotherapy: a role for histamine?

  2000cites this paper
• Adjuvant histamine in cancer immunotherapy.

  2000cites this paper
• An overview of cancer immunotherapy

  2000cites this paper
• Duration of survival for disseminated malignant melanoma: results of a meta-analysis.

  2000cites this paper
• Histamine: A Novel Approach to Cancer Immunotherapy

  2000cites this paper
• Validation of the internal reference technique for microdialysis measurements of interstitial histamine in the rat.

  1999cites this paper
• Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation.

  1999cites this paper
• Impediments to successful immunotherapy.

  1999cites this paper
• Histamine Protects T Cells and Natural Killer Cells Against Oxidative Stress

  1999cites this paper
• The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation.

  1998cites this paper
• Histamine and cytokine therapy.

  1998cites this paper
• Histamine and interleukin-2 in acute myelogenous leukemia.

  1997cites this paper
• Histamine in cancer immunotherapy.

  1997cites this paper
• Systemic therapy of malignant melanoma

  1997cites this paper
• Mast cell-tumor cell interactions: for or against tumour growth and metastasis?

  1997cites this paper
• Histamine, cimetidine and colorectal cancer

  1996cites this paper
• Histaminergic Regulation of Natural Killer Cell‐Mediated Clearance of Tumour Cells in Mice

  1996cites this paper
• Remission maintenance therapy with histamine and interleukin‐2 in acute myelogenous leukaemia

  1996cites this paper
• Histaminergic Regulation of NK‐Cells: Protection Against Monocyte‐Induced Apoptosis

  1996cites this paper
• Histaminergic regulation of pancreatic beta-cell replication and insulin secretion.

  1995cites this paper